Safety and Pharmacokinetics of Abicipar Pegol Intravitreal Injections in Japanese Patients With Neovascular AMD
Status:
Completed
Trial end date:
2018-10-08
Target enrollment:
Participant gender:
Summary
This study will evaluate the safety and to characterize the systemic pharmacokinetics of free
and vascular endothelial growth factor (VEGF)-bound abicipar following multiple monthly
intravitreal injections of abicipar in Japanese patients with neovascular age-related macular
degeneration (AMD).